The Quest for Optimal Therapy: Sofosbuvir and Ribavirin in Chronic Hepatitis C – A Systematic Review
DOI:
https://doi.org/10.56570/jimgs.v2i2.126Keywords:
Sofosbuvir, Ribavirin, Chronic Hepatitis-C, Cirrhosis, Safety, EfficacyAbstract
Background. Chronic Hepatitis C (CHC) infection leads to liver cirrhosis, liver failure and hepatocellular carcinoma. It is mostly treated with Sofosbuvir and ribavirin or in combination with other Direct-acting antivirals (DAA's). Method. This was a systematic review Comparing the safety and efficacy of Sofosbuvir and ribavirin in Chronic Hepatitis C. Studies including patients taking Sofosbuvir and ribavirin, or both were included with a specific focus on Cirrhosis patients. Results. Sustained Virological Response (SVR) from included studies showed above 90% overall. The study found that Sofosbuvir and Ribavirin were safe and effective in mild and moderate cirrhosis, but SVR rates dropped to 57% for decompensated cirrhosis. Conclusion. Sofosbuvir and ribavirin are the most effective, well-tolerated, and shortest treatment for chronic hepatitis C, making it a curable disease.References
Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019;26(3):323-328. doi:10.1111/jvh.13034
Tang L, Kamat M, Shukla A, et al. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdiscip Perspect Infect Dis. 2018;2018:9124604. Published 2018 Oct 1. doi:10.1155/2018/9124604
Yeon JE. Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?. Clin Mol Hepatol. 2018;24(3):294-296. doi:10.3350/cmh.2018.1009
Butt N, Reema S, Ali Khan M, et al. Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus. 2019;11(4):e4458. Published 2019 Apr 14. doi:10.7759/cureus.4458
Kim YM, Kim SB, Song IH, et al. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol. 2018;24(3):311-318. doi:10.3350/cmh.2017.0070
Miyasaka A, Yoshida Y, Suzuki A, Masuda T, Okamoto H, Takikawa Y. Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review. Medicine (Baltimore). 2020;99(41):e22650. doi:10.1097/MD.0000000000022650
Pellicelli A, Messina V, Giannelli V, et al. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. Gut Liver. 2020;14(3):357-367. doi:10.5009/gnl18269
Chen CC, Tung SY, Wei KL, et al. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc. 2020;119(1 Pt 3):532-537. doi:10.1016/j.jfma.2019.07.028
Xu XW, Wu XX, Chen KD, et al. Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study. Medicine (Baltimore). 2018;97(38):e12403. doi:10.1097/MD.0000000000012403
Orr C, Xu W, Masur H, Kottilil S, Meissner EG. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020;20(1):929. Published 2020 Dec 4. doi:10.1186/s12879-020-05657-5
Jang ES, Kim KA, Kim YS, et al. Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Gut Liver. 2020;14(6):775-782. doi:10.5009/gnl19260
Mita E, Liu LJ, Shing D, et al. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan. Intern Med. 2023;62(10):1405-1414. doi:10.2169/internalmedicine.0067-22
Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. J Clin Exp Hepatol. 2019;9(1):4-12. doi:10.1016/j.jceh.2018.02.009
Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect. 2021;9(4):e00811. doi:10.1002/prp2.811
Liu CH, Chen CY, Su WW, et al. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clin Mol Hepatol. 2021;27(4):575-588. doi:10.3350/cmh.2021.0155
Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother. 2020;121:109657. doi:10.1016/j.biopha.2019.109657
Han SY, Woo HY, Heo J, et al. The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2. Korean J Intern Med. 2021;36(3):544-556. doi:10.3904/kjim.2018.329
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372: n71. 10.1136/bmj. n71
https://www.ohri.ca/programs/clinical_epidemiolog y/oxford.asp.
https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials.
https://jbi.global/critical-appraisal-tools.
Xie Q, Xuan JW, Tang H, et al. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol. 2019;11(5):421-441. doi:10.4254/wjh.v11.i5.421
Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial [published correction appears in JAMA. 2013 Nov 13;310(18):1987. Dosage error in article text]. JAMA. 2013;310(8):804-811. doi:10.1001/jama.2013.109309
Wei B, Ji F, Yeo YH, et al. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018;5(1):e000207. Published 2018 Jun 29. doi:10.1136/bmjgast-2018-000207
Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?. Hepat Mon. 2014;14(11):e25540. Published 2014 Nov 23. doi:10.5812/hepatmon.25540
https://www.uspharmacist.com/article/the-evolving-management-of-hepatitis-c-virus#:~:text=Nonstructural%20Protein%205B%20(N S5B)%20Inhibitors,with%20other%20agents%20or% 20ribavirin
Shiha G, Esmat G, Hassany M, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2019;68(4):721-728. doi:10.1136/gutjnl-2017-315906
Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology. 2019;156(2):431-445. doi:10.1053/j.gastro.2018.10.024
Nakamura M, Kanda T, Haga Y, et al. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol. 2016;8(3):183-190. doi:10.4254/wjh.v8.i3.183
